KRASG12C inhibition enhances immunogenicity in KRASG12C-mutant colorectal cancer

被引：0
|
作者：
Patel, Parasvi S.
Tian, Jun
de la Cruz, Ferran Fece
Curtis, Jacquelyn
Panda, Apekshya
Oka, Tomonori
Demehri, Shadmehr
Sade-Feldman, Moshe
Koptez, Scott
Corcoran, Ryan B.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB366
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB366
引用
收藏
页数：2
相关论文
共 50 条
  • [31] KRASG12C inhibitor: combing for combination
    Chakraborty, Atanu
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2020, 48 (06) : 2691 - 2701
  • [32] The Effective Targeting of KRASG12C Elusiveness
    Elez, Filiation Elena
    Tabernero, Josep
    CANCER CELL, 2020, 38 (06) : 785 - 787
  • [33] Vertical inhibition overcomes adaptive resistance to KRASG12C inhibition
    Ryan, Meagan B.
    de la Cruz, Ferran Fece
    Phat, Sarah
    Myers, David T.
    Shahzade, Heather A.
    Hong, Catriona B.
    Corcoran, Ryan B.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [34] Resistance looms for KRASG12C inhibitors
    Aaron N. Hata
    Alice T. Shaw
    Nature Medicine, 2020, 26 : 169 - 170
  • [35] RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers
    Nichols, Robert J.
    Yang, Y. C.
    Cregg, Jim
    Schulze, Chris J.
    Wang, Zhican
    Dua, Richa
    Jiang, Jingjing
    Garrenton, Lindsay S.
    Nasholm, Nicole
    Bermingham, Alun
    Knox, John E.
    Seamon, Kyle
    Longhi, Michael
    Chou, Kang-Jye
    Li, Shaoling
    Wildes, David P.
    Singh, Mallika
    Koltun, Elena S.
    Gill, Adrian L.
    Smith, Jacqueline A. M.
    CANCER RESEARCH, 2022, 82 (12)
  • [36] Resistance looms for KRASG12C inhibitors
    Hata, Aaron N.
    Shaw, Alice T.
    NATURE MEDICINE, 2020, 26 (02) : 169 - 170
  • [37] Mechanisms of Resistance to KRASG12C Inhibitors
    Dunnett-Kane, Victoria
    Nicola, Pantelis
    Blackhall, Fiona
    Lindsay, Colin
    CANCERS, 2021, 13 (01) : 1 - 14
  • [38] SOTORASIB IS ACTIVE IN KRASG12C-MUTANT NON-SMALL CELL LUNG CANCER
    Skoulidis, F.
    Li, B. T.
    Dy, G. K.
    Price, T. J.
    Falchook, G. S.
    Wolf, J.
    CANCER DISCOVERY, 2021, 11 (08) : 1870 - 1870
  • [39] Sotorasib/SHP2 inhibitors combo, KRASG12C(ON)I and RASMULTI(ON)I effectively target KRASG12C tumors developing secondary resistance to Sotorasib via KRASG12C amplification
    Solanki, Hitendra S.
    Imbody, Denis
    Desai, Bina
    Kato, Ryoji
    Stewart, Paul A.
    Stern, Yaakov
    Majumder, Anurima
    Bridenstine, Liznair
    Sarca, Bhaswati
    Miroshnychenko, Dada
    Aronchik, Ida
    Marusyk, Andriy
    Haura, Eric B.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [40] Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
    Novoplansky, Ofra
    Jagadeeshan, Sankar
    Prasad, Manu
    Yegodayev, Ksenia M.
    Marripati, Divyasree
    Abu Shareb, Raghda
    Greenshpan, Yariv
    Mathukkada, Sooraj
    Ben-Lulu, Talal
    Bhattacharya, Baisali
    Porgador, Angel
    Kong, Dexin
    Braegelmann, Johannes
    Gutkind, J. Silvio
    Elkabets, Moshe
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
12345